and 33% (2/6), respectively. Eight patients (50%) discontinued treatment for the following reasons: primary failure (n=3), secondary failure (n=1), suboptimal clinical improvement (n=2), recurrent infections (n=1), and quiescent Crohn’s disease (n=1).
The treatment of HS is challenging and there is a paucity of effective therapeutic options for patients with moderateto- severe disease. This retrospective chart review found ustekinumab to be an effective and safe option for patients with refractory HS and for patients with co-existing HS and Crohn’s disease. Adverse effects and complications lead to treatment withdrawal in one patient. This is an uncontrolled, retrospective review with a small sample size. Further prospective studies using validated assessment tools are warranted to establish the place of ustekinumab in the current treatment armamentarium for HS.
The treatment of HS is challenging and there is a paucity of effective therapeutic options for patients with moderateto- severe disease. This retrospective chart review found ustekinumab to be an effective and safe option for patients with refractory HS and for patients with co-existing HS and Crohn’s disease. Adverse effects and complications lead to treatment withdrawal in one patient. This is an uncontrolled, retrospective review with a small sample size. Further prospective studies using validated assessment tools are warranted to establish the place of ustekinumab in the current treatment armamentarium for HS.
DISCLOSURES
B.K. conducts clinical trials for AbbVie, Almirall, Merck Sharpe &
Dohme, Novartis, and UCB Pharma. B.K. is in receipt of research
grants from AbbVie, Janssen, and Almirall; he has acted as a
consultant and/or speaker for AbbVie, Almirall, Janssen, LEO
Pharma, Lilly, Novartis, and UCB.
REFERENCES
1. Zouboulis CC, Desai N, Emtestam L et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015; 29: 619– 44.
2. Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010; 62: e701
3. Dufour DN, Emtestam L, Jemec GBHidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgraduate Medical Journal. 2014;90:216-221.
4. Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, Desai N, Goodacre TEE, Piguet V, Pink AE, Exton LS, Mohd Mustapa MF. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-1017.
5. Schlapbach C, Hanni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011
6. Blok, J. L., Li, K., Brodmerkel, C., Horvátovich, P., Jonkman, M. F., & Horváth, B. (2016). Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 174(4), 839–846. doi:10.1111/bjd.14338
2. Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010; 62: e701
3. Dufour DN, Emtestam L, Jemec GBHidradenitis suppurativa: a common and burdensome, yet under-recognised, inflammatory skin disease. Postgraduate Medical Journal. 2014;90:216-221.
4. Ingram JR, Collier F, Brown D, Burton T, Burton J, Chin MF, Desai N, Goodacre TEE, Piguet V, Pink AE, Exton LS, Mohd Mustapa MF. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018. Br J Dermatol. 2019 May;180(5):1009-1017.
5. Schlapbach C, Hanni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011
6. Blok, J. L., Li, K., Brodmerkel, C., Horvátovich, P., Jonkman, M. F., & Horváth, B. (2016). Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 174(4), 839–846. doi:10.1111/bjd.14338
AUTHOR CORRESPONDENCE
Aoife Hollywood hollywood.aoife@gmail.com
